Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial -

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Haematology
Specialities: Cancers | Haematological disorders
Summary
At a median follow-up of 31.5 months, this study (n=314) reports no significant difference in overall survival between lenalidomide and placebo, although progression-free survival was significantly longer with lenalidomide (median 33.9 v 9.2months respectively; HR 0.40, p<0.0001)
UKMi comment

A related editorial discusses the findings of this study, suggesting that the role of lenalidomide maintenance beyond first-line therapy for chronic lymphocytic leukaemia might be somewhat limited.
Related links: Editorial